Skip to main content
Smart Investors Daily
AB

NASDAQ · ABOS

Acumen Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.21

Up+$0.00 (+0.93%)

Updated Nov 17, 2026, 1:57 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
190.2M
P/E ratio
-1.43
Dividend yield
0.00%
52-week range
$0.19 – $3.60
Volume
2.78M
Avg. volume
585.74K

Price performance · ABOS

ABOS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

ABOS closed at $0.21 after 20 trading sessions, down 87.91% for the selected period.

Last close
$0.21
Period change
-87.91%
Period low
$0.21
Period high
$2.38
Daily close
View OHLC price history
ABOS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$0.2229$0.227$0.1916$0.2142.78M
Nov 12, 2026$0.228$0.228$0.2141$0.218885.93K
Nov 11, 2026$0.2278$0.2353$0.2254$0.231.22M
Nov 10, 2026$0.2334$0.2484$0.228$0.231.86M
Nov 9, 2026$0.22$0.248$0.22$0.2372.72M
Nov 6, 2026$0.2121$0.2274$0.2121$0.22352.01M
Nov 5, 2026$0.2162$0.2199$0.1911$0.21386.17M
Nov 4, 2026$0.23$0.2496$0.2163$0.21638.68M
Nov 3, 2026$0.2397$0.2481$0.225$0.23446.16M
Nov 2, 2026$0.2006$0.2668$0.198$0.239733.72M
Oct 30, 2026$0.3444$0.352$0.2092$0.210168.1M
Oct 29, 2026$2.40$2.52$2.285$2.29808.04K
Oct 28, 2026$2.28$2.495$2.2574$2.381.41M
Oct 27, 2026$2.25$2.3699$2.10$2.261.8M
Oct 26, 2026$2.13$2.42$1.97$2.271.65M
Oct 23, 2026$2.05$2.05$1.895$1.98541.79K
Oct 22, 2026$2.03$2.14$2.01$2.06569.49K
Oct 21, 2026$2.00$2.08$1.99$2.03397.71K
Oct 20, 2026$1.78$2.0699$1.764$2.015784.62K
Oct 19, 2026$1.70$1.78$1.67$1.77274.68K

Latest ABOS news

The latest Smart Investors Daily articles mentioning ABOS.

ABOS research

Overview

Company profile and research snapshot.

Company profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
11
ABOS recent ratings
DateFirmRatingTarget
Nov 2, 2026BTIGBuy—
Oct 30, 2026CitigroupNeutral—
Sep 16, 2026BTIGBuy—
Sep 15, 2026CitigroupBuy—
Mar 26, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 3, 2026

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.